| Id: | acc0018 |
| Group: | 1sens |
| Protein: | Rb |
| Gene Symbol: | RB1 |
| Protein Id: | P06400 |
| Protein Name: | RB_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser811 |
| Site Sequence: | GNIYISPLKSPYKISEGLPTP |
| Disease Category: | Cancer |
| Disease: | Pancreas Cancer |
| Disease Subtype: | |
| Disease Cellline: | CAPAN1 |
| Disease Info: | |
| Drug: | temozolomide(TMZ) |
| Drug Info: | "Temozolomide (TMZ) is an alkylating chemotherapeutic agent primarily used in the treatment of glioblastoma multiforme, functioning by inhibiting DNA synthesis in cancer cells through methylation of guanine residues, and is often administered in combination with radiotherapy." |
| Effect: | inhibit |
| Effect Info: | "Methionine stress enhances the sensitivity of pancreatic tumor cells to DNA alkylating drugs, 5-fluorouracil, and radiation. Moreover, under methionine stress conditions, the sensitivity of cells to temozolomide is increased." |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 16170025 |
| Sentence Index: | 16170025_11 |
| Sentence: | Increased sensitivity of pancreatic tumor cell lines to temozolomide is shown under methionine stress conditions and is attributed in part to diminished O(6)-methylguanine-DNA methyltransferase and possibly to inhibition of the cell cycle progression. |
Sequence & Structure:
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| RB1-Ser811 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.326 |
| COAD | -0.737 |
| HGSC | 1.982 |
| ccRCC | |
| GBM | -0.759 |
| HNSC | 0.242 |
| LUAD | |
| LUSC | -1.24 |
| non_ccRCC | |
| PDAC | 0.434 |
| UCEC | -0.248 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 811 | D | Skin cancer | Phosphorylation | 23888052 |
| S | 811 | U | Intraocular melanoma | Phosphorylation | 10969768 ; 10969768 |
| S | 811 | U | Bladder cancer | Phosphorylation | 22787429 |
| S | 811 | U | Neuroendocrine cancer/carcinoma | Phosphorylation | 24135281 |
| S | 811 | U | Melanoma | Phosphorylation | 15502804 ; 15502804 |
| S | 811 | U | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 23408967 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | AZD8055 | 6.0392 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Tideglusib | 4.8968 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Staursporin | 11.4859 | - | |
| P06400 | RB1 | P | Ser811 | IPGGNIYISPLKS(ph)PYK | A549 | Pictilisib | 8.291 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Pictilisib | 10.5849 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | PD325901 | 9.0766 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Nintedanib | 8.0388 | - | |
| P06400 | RB1 | P | Ser811 | IPGGNIYISPLKS(ph)PYK | A549 | Dasatinib | 2 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Dasatinib | 6.2296 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Dasatinib | 6.7852 | - | |
| P06400 | RB1 | P | Tyr805;Ser811 | IPGGNIY(ph)ISPLKS(ph)PYK | A549 | Dasatinib | 10.7569 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A549 | Dactolisib | 10.8604 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Afatinib | 7.2979 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Gefitinib | 6.2454 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Gefitinib | 8.2708 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Gefitinib | 7.7927 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Dasatinib | 9.0028 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Dasatinib | 8.9649 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Dasatinib | 2 | - | |
| P06400 | RB1 | P | Ser811 | IPGGNIYISPLKS(ph)PYK | A431 | Dasatinib | 5.5362 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Dasatinib | 12.3408 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Afatinib | 7.9015 | - | |
| P06400 | RB1 | P | Ser807;Ser811 | IPGGNIYIS(ph)PLKS(ph)PYK | A431 | Afatinib | 8.3885 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
